Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models
about
Maximizing the Therapeutic Potential of HSP90 InhibitorsAdapt, Recycle, and Move on: Proteostasis and Trafficking Mechanisms in MelanomaThe Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK ExpressionBeyond standard therapy: drugs under investigation for the treatment of gastrointestinal stromal tumor.3D matrix-based cell cultures: Automated analysis of tumor cell survival and proliferation.The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells.A Novel Plant Sesquiterpene Lactone Derivative, DETD-35, Suppresses BRAFV600E Mutant Melanoma Growth and Overcomes Acquired Vemurafenib Resistance in Mice.HSP70 Inhibition Limits FAK-Dependent Invasion and Enhances the Response to Melanoma Treatment with BRAF Inhibitors.The Broad Stroke of Hsp90 Inhibitors: Painting over the RAF Inhibitor Paradox.Activity-Based Protein Profiling Shows Heterogeneous Signaling Adaptations to BRAF Inhibition.HECTD3 Mediates an HSP90-Dependent Degradation Pathway for Protein Kinase Clients.Combine and conquer: challenges for targeted therapy combinations in early phase trials.Emergence of resistance to tyrosine kinase inhibitors in non-small-cell lung cancer can be delayed by an upfront combination with the HSP90 inhibitor onalespib.Improving patient outcomes to targeted therapies in melanoma.The pharmacogenomics of drug resistance to protein kinase inhibitors.Blocking the survival of the nastiest by HSP90 inhibitionA phase I trial of the intravenous Hsp90 inhibitor alvespimycin (17-DMAG) in patients with relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma.XL888 Limits Vemurafenib-Induced Proliferative Skin Events by Suppressing Paradoxical MAPK Activation.Wild-type KRAS is a novel therapeutic target for melanoma contributing to primary and acquired resistance to BRAF inhibition.Targeting CDK2 overcomes melanoma resistance against BRAF and Hsp90 inhibitors.17-AAG inhibits vemurafenib-associated MAP kinase activation and is synergistic with cellular immunotherapy in a murine melanoma model.Combined BRAF and HSP90 Inhibition in Patients with Unresectable -Mutant Melanoma
P2860
Q26798318-06A797E9-ECF4-49F9-AAD2-834AF6A279E6Q28069018-A74D94E1-C2C1-4313-BD23-168FA2CDC0B5Q35691278-F1EABB5E-7BE4-4CA3-A9AF-EB4B129888C0Q36125976-0D20938A-268B-4E6C-815D-40F2FCB9BE8FQ36525375-2E796335-8EBA-4A7A-BB1A-4AF20037FCB5Q36546425-17AF26A0-ADDE-41D5-A88B-4F6B25E83D52Q36971266-E8DD50DB-ED67-4DAD-896A-AF6650AE67DEQ37082577-1CC45A14-D125-428D-AF16-B594E374CC9BQ38412577-B382A43E-235D-4720-89F4-5FAC99FAEF81Q38439387-057AA4EA-B5CC-4303-8614-8D801A822A92Q38715481-0DBCD48A-80A1-49AB-8394-F17A76C3DAD8Q38734451-A9B9BF20-CA30-4B60-A355-F126C679C528Q38737681-52F15E82-755A-4FC5-9944-61A092B35BF0Q38823508-42E7F2C9-8D2D-4581-A3DB-AE6713D7D581Q38952751-D4B18F02-E558-44C2-A26B-3096EAB56628Q39995934-E2501CB2-1DC7-4A6A-8E74-F4B9F90F02A6Q41827341-5FFBBB25-3679-438F-8208-290EBF8946D0Q41897553-B8F22310-CF81-44AF-B2DB-793E65FD94CDQ47566725-4081E078-CEBD-4CF1-887C-AA652E5CB510Q52673303-3482E9A1-82F3-4569-A59F-1822817E80DCQ54983509-7515EFEF-9F07-4FC7-A2FA-AA79FD9FB984Q58747510-A4BD06FA-D8DB-4D85-ADE3-176FC7BF92E1
P2860
Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Inhibition of HSP90 by AT13387 ...... inhibition in melanoma models
@ast
Inhibition of HSP90 by AT13387 ...... inhibition in melanoma models
@en
Inhibition of HSP90 by AT13387 ...... inhibition in melanoma models
@nl
type
label
Inhibition of HSP90 by AT13387 ...... inhibition in melanoma models
@ast
Inhibition of HSP90 by AT13387 ...... inhibition in melanoma models
@en
Inhibition of HSP90 by AT13387 ...... inhibition in melanoma models
@nl
prefLabel
Inhibition of HSP90 by AT13387 ...... inhibition in melanoma models
@ast
Inhibition of HSP90 by AT13387 ...... inhibition in melanoma models
@en
Inhibition of HSP90 by AT13387 ...... inhibition in melanoma models
@nl
P2093
P2860
P1476
Inhibition of HSP90 by AT13387 ...... inhibition in melanoma models
@en
P2093
Ana M Rodriguez-Lopez
H Eirik Haarberg
Joanne M Munck
John F Lyons
Keisha Hearn
Kim H T Paraiso
Mohammad Azab
Neil T Thompson
Nicola G Wallis
Tomoko Smyth
P2860
P304
P356
10.1158/1535-7163.MCT-14-0452
P577
2014-10-27T00:00:00Z